Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
Total Valuation
Cogent Biosciences has a market cap or net worth of $6.00B. The enterprise value is $1.75B.
Market Cap$6.00B
Enterprise Value$1.75B
Share Statistics
Cogent Biosciences has 152,053,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding152,053,960
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cogent Biosciences’s return on equity (ROE) is -1.00 and return on invested capital (ROIC) is -100.23%.
Return on Equity (ROE)-1.00
Return on Assets (ROA)-0.78
Return on Invested Capital (ROIC)-100.23%
Return on Capital Employed (ROCE)-1.01
Revenue Per Employee0.00
Profits Per Employee-1.25M
Employee Count205
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cogent Biosciences is ―. Cogent Biosciences’s PEG ratio is -1.92.
PE Ratio―
PS Ratio0.00
PB Ratio3.16
Price to Fair Value3.16
Price to FCF-3.89
Price to Operating Cash Flow-17.05
PEG Ratio-1.92
Income Statement
In the last 12 months, Cogent Biosciences had revenue of 0.00 and earned -255.86M in profits. Earnings per share was -2.46.
Revenue0.00
Gross Profit0.00
Operating Income-275.94M
Pretax Income-255.86M
Net Income-255.86M
EBITDA-271.59M
Earnings Per Share (EPS)-2.46
Cash Flow
In the last 12 months, operating cash flow was -245.92M and capital expenditures -818.00K, giving a free cash flow of -246.73M billion.
Operating Cash Flow-245.92M
Free Cash Flow-246.73M
Free Cash Flow per Share-1.62
Dividends & Yields
Cogent Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.79
52-Week Price Change404.46%
50-Day Moving Average28.45
200-Day Moving Average13.76
Relative Strength Index (RSI)61.92
Average Volume (3m)4.03M
Important Dates
Cogent Biosciences upcoming earnings date is Mar 17, 2026, TBA (Confirmed).
Last Earnings DateNov 3, 2025
Next Earnings DateMar 17, 2026
Ex-Dividend Date―
Financial Position
Cogent Biosciences as a current ratio of 5.32, with Debt / Equity ratio of 39.13%
Current Ratio5.32
Quick Ratio5.32
Debt to Market Cap<0.01
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cogent Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cogent Biosciences EV to EBITDA ratio is -2.64, with an EV/FCF ratio of -3.50.
EV to Sales0.00
EV to EBITDA-2.64
EV to Free Cash Flow-3.50
EV to Operating Cash Flow-3.51
Balance Sheet
Cogent Biosciences has $390.89M in cash and marketable securities with $60.56M in debt, giving a net cash position of $330.33M billion.
Cash & Marketable Securities$390.89M
Total Debt$60.56M
Net Cash$330.33M
Net Cash Per Share$2.17
Tangible Book Value Per Share$2.47
Margins
Gross margin is -29.03%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-29.03%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cogent Biosciences is $45.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$45.50
Price Target Upside15.04% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast4.32%